Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afimetoran Pharmacokinetics with Famotidine in Healthy Participants
NCT05866627Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2023
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of afimetoran in systemic lupus erythematosus (SLE) (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration up to 20 Days, Time to attain maximum observed plasma concentration up to 20 Days and 1 more. Started Jul 2023; status: completed.
02
Drugs
afimetoran
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT05866627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05866627.